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Abstract
Cervical cancer is primarily caused by human papillomavirus (HPV) and is the second
most common cause of cancer-related mortality among women. Female college students
may be at risk for contracting HPV based on their sexual behavior. Following the release
of the HPV vaccine, Gardasil®, this cross-sectional study was developed to (1) determine
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awareness of HPV and Gardasil®, (2) assess attitudes, behaviors, and beliefs about the
HPV vaccine, and (3) identify information sources that female college students are
accessing. Female college students voluntarily completed a self-administered
questionnaire. Statistical analyses included descriptive statistics, Pearson’s correlations
and paired sample t-tests. Sexually active respondents would recommend the HPV
vaccine to others and disagreed that vaccination would encourage risky sexual behavior.
Correlations were identified on how self-reported knowledge influenced attitudes,
behaviors, and beliefs regarding the HPV vaccine. These findings should assist in
developing integrated public health education efforts for HPV vaccination that are
targeted towards this at-risk population.
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Introduction
Background
Cervical cancer is a global public health issue that is second to breast cancer in overall
cancer-related mortality among women. Cervical cancer presents a distinctive public
health challenge since it is caused by a sexually transmitted virus; is gender specific; and
primary and secondary public health prevention efforts target an expansive age range of
women. 1 According to the American Cancer Society, in the United States (U.S.),
approximately 9,710 women were diagnosed with cervical cancer, and 3,700 died from
this disease in 2006. 2 On a global level, approximately 500,000 cases of cervical cancer
are diagnosed on an annual basis which accounts for approximately 250,000 deaths
among women. 3-6
The majority of cervical cancer is caused by a persistent infection with the human
papillomavirus (HPV). 7 The Papanicolaou (Pap) cytology test has proven to be an
effective screening tool in identifying the precursor lesion associated with HPV infection. 8
HPV is a DNA virus with more than 100 different types having been identified;
approximately 30 types are sexually transmitted. Low risk HPV types, HPV-6 and HPV11, are responsible for 90% of genital warts cases. High risk HPV types, HPV-16 and
HPV-18, account for approximately 70% of cervical cancer cases. 9 HPV is one of the
most common sexually transmitted infections in the world and studies suggest that
approximately 90% of HPV infections resolve themselves within two years. It is the
percentage of HPV infections that do not resolve themselves that have the potential to
contribute to cervical cancer. 10,11 The prevalence of HPV has been found to be highest
among young persons within the first few years after sexual activity is initiated. The
prevalence of HPV infection was found to be highest among females aged 20-24 years.
12,13

Each year, approximately 6.2 to 7.5 million Americans become infected with genital

HPV. The Centers for Disease Control and Prevention (CDC) reported that, unless
vaccinated, approximately 80% of sexually active women will acquire HPV by the age of
50. 14
In June 2006, the Food and Drug Administration (FDA) approved the first prophylactic
human papillomavirus vaccine, Gardasil ® , that has been shown to be effective against
HPV types 6 and 11 which contribute to genital warts, and HPV types 16 and 18 which
contribute to cervical cancer. Efficacy rates of the vaccine for clinical outcomes have
approached 100% in preventing infection and disease in clinical trials of women aged 16
to 24. 15 The CDC’s Advisory Committee on Immunization Practices currently
recommends universal administration of three interval doses of the HPV vaccine,
Gardasil ® , in girls 11 or 12 years of age. The recommendation also allows for females
aged nine to 26 years to be vaccinated at the discretion of their physician. 16 Predictive
public health strategies, such as administering the prophylactic HPV vaccine to all 12year-old girls in the U.S., estimate that more than 1,300 cervical cancer deaths among this
susceptible population could be prevented. In addition, this public health approach could
also prove to be cost effective if Pap tests were conducted at a later age and less
frequently. Furthermore, a computer-based model estimated that HPV vaccination at age
12 and Pap tests every three years starting at age 25 could potentially reduce a woman’s
lifetime risk of cervical cancer by 94%. 17,18

Purpose
Early age of first sexual intercourse is associated with greater susceptibility to HPV
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infection, possibly due to the immature status of the cervix. 19 In the U.S., sexual activity
begins in ninth grade for 29.3% of girls, and 62.4% of twelfth grade girls report prior
sexual activity. 20 Early sexual behavior warrants the importance of a prophylactic HPV
vaccine for younger females, prior to becoming sexually active, in order to provide the
most public health benefit. Furthermore, factors that have been associated with an
increased risk of acquiring HPV include age, condom use, increasing cumulative number
of sexual partners, sex with a new partner, knowing a partner less than a year, and
marital status. 12,13,21,22
HPV has been detected in 99.7% of cervical cancer cases. 7 Dunne et al. found the
overall prevalence of HPV to be 26.8% in U.S. females aged 14 to 59 years and 24.5%
among females aged 14 to 19, and HPV prevalence was 44.8% for females 20 to 24
years of age and 27.4% for females aged 25 to 29 years, and then decreased at older
ages, possibly due to acquired immunity. 13 Moreover, several studies have shown that
sexually active female college students in the 20-24 age group are often unaware of HPV
and become aware of HPV only after being diagnosed with the HPV infection by a
healthcare provider. 23,24 Thus, college age women may be at high risk for contracting
HPV.
Kahn et al. explored the following variables in young women prior to the introduction of
Gardasil ® : knowledge about HPV and the HPV vaccine; personal beliefs about HPV
vaccination; belief that others would approve of HPV vaccination; number of sexual
partners; and perceived support of healthcare provider, partner, and parents. They found
that all factors were significantly associated with the intention to receive the HPV vaccine.
25

Boehner et al. examined the acceptability of an HPV vaccine among college students

several years before the HPV vaccine became available to the public and found that 74%
of female college students would accept such a vaccine. 26 The purpose of our
exploratory analysis is to expand upon this previous research by investigating, following
the release of Gardasil ® , (1) what information sources female college students are
accessing about the HPV vaccine; (2) how this knowledge has influenced attitudes,
behaviors, and beliefs regarding the HPV vaccine among this population with respect to
recommending the HPV vaccine to others, and whether or not receiving the HPV vaccine
would encourage risky sexual behavior; and (3) correlations between social behavior
(e.g., sexual practices, relationship status) and one’s concern about HPV infection and
recommending the HPV vaccine to others. This information, collectively, may offer
different views on a pertinent health issue that health educators may want to consider as
they develop integrated public health education and immunization initiatives aimed at
reducing the burden of HPV infection among female college students.

Methods
A cross-sectional study design was utilized for this exploratory analysis, in order to
administer a self-report questionnaire to a relevant sample of 361 female college students
from a large, public, state-supported Northeastern university in 2007. The university’s
Institutional Review Board approved the study. Questionnaires were administered over a
period of four weeks at different times and at several locations (e.g., University Health
Services, Alpha Phi sorority, health class, aerobics class, and a choral rehearsal) on the
university’s campus from the end of February through March 2007. Questionnaires were
also distributed on campus to female college students enrolled at the university who were
entering or departing scheduled classes and events. The anonymous surveys took an
average of seven minutes to complete and were immediately collected from the
participants upon completion. University Health Services administered surveys to female
students as they waited for their appointments. Completed surveys were returned to the
reception desk and were collected in a locked collection box.
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All questionnaires had a cover letter attached that explained the purpose of the study and
emphasized the anonymity and confidentiality of the results. Students were told to keep
this letter for their records. There were no incentives for participating in this study.
Additional open ended comments from the participants were recorded at the end of the
survey.
The 23-item questionnaire was designed to determine demographic information, level, and
source of self-reported knowledge about HPV and the HPV vaccine and attitudes,
behaviors, and beliefs about the HPV vaccine. Revisions were made during the pilot
testing phase of the questionnaire. Ambiguities associated with the survey content were
not identified during test trials that were conducted prior to official questionnaire
administration.
Respondents were asked if they knew what HPV was and if they had heard of the HPV
vaccine, Gardasil ® , prior to this survey (“Yes”/”No”/”Not sure” to both). In order to
determine sources of information of the vaccine, respondents were asked to choose from
the following sources: “Tell Someone” commercial, “One Less” commercial, talk show,
news show, magazine advertisements, magazine articles, radio, newspaper articles,
medical journals, Merck Pharmaceutical, Inc. web site, thehpvtest.com web site, general
practitioner, nurse, other health professional, University Health Services, family, friends,
and other. Respondents were instructed to circle all that applied to them.
Respondents were then asked if they would get the HPV vaccine if it were offered for free.
Those who responded “No” or “Not sure” were asked a follow-up question to determine
the reason for their response. There was also a question to determine what behavior
changes have resulted from knowing about the HPV vaccine. Examples included: getting
vaccinated against HPV; speaking with a healthcare professional about the HPV vaccine;
sharing knowledge with family or friends; and engaging in further information gathering
about the HPV vaccine and the link between cervical cancer and HPV.
Finally, information regarding the respondent’s attitude about the idea that HPV
vaccination may lead to risky sexual behavior, a current controversial topic, was
collected. Respondents were asked a series of questions to determine the degree to
which they agree with statements about the HPV vaccine, such as should females
between the ages of nine and 26 years of age get the HPV vaccine, and whether or not
they were personally concerned about acquiring HPV. The questions were analyzed on a
three-point scale, “Agree”/”Disagree”/”Not sure.”
All data were analyzed using the Statistical Package for Social Sciences (SPSS), Version
15.0 for Windows. Descriptive analyses were done for each of the following participant
responses: specific college the participant was enrolled in at the university; age (age
groups analyzed: 17-18, 19-21, 21-24, ≥25 years); race; if have had sexual intercourse;
age at which first had sexual intercourse; number of sexual partners (the number of
sexual partners analyzed: 0, 1, 2, 3-5, ≥6); condom use; relationship status; overall health
status; if receive regular Pap screening tests; knowledge of HPV; heard of Gardasil ®
before survey; knowledge of the HPV vaccine; would get the HPV vaccine if it were
offered for free; reasons for not getting the HPV vaccine if it were offered for free;
behavior change(s) as a result of knowledge of the HPV vaccine; likelihood of
recommending the HPV vaccine to others; agreement that females between the ages
nine and 26 should get the HPV vaccine; belief that the HPV vaccine may encourage
risky sexual behavior; and concern about possibly acquiring HPV.
Cross-tabulation analyses were done for the questions of interest and all demographic
variables, as well as self-reported knowledge of HPV and the HPV vaccine. These

https://ispub.com/IJH/9/2/9245[1/5/2015 9:06:32 AM]

Internet Scientific Publications
questions included: would get the HPV vaccine if it were offered for free; likelihood of
recommending the HPV vaccine to others; agreement that females between the ages
nine and 26 should get the HPV vaccine; agreement that HPV vaccination against a
sexually transmitted infection may encourage risky sexual behavior; and concern about
possibly acquiring HPV. Pearson’s chi-square tests and two-tailed t-tests were done to
assess relationships between two variables. For statistical tests, P-values less than 0.05
were considered to be statistically significant.

Results
The demographic and behavioral characteristics of female undergraduate respondents are
shown in Table 1. Two hundred ninety-three of 361 surveys (81% response rate) were
completed and returned by female college students enrolled at a large Northeastern State
University. Female students, aged 18 to 34 years, voluntarily participated in the
anonymous study. The mean age of the respondents was 20.4 years (standard deviation
[SD] =0.125), and 93.5% of respondents were Caucasian. Based on a comparison to
information compiled by the university’s Office of Institutional Research, the population
demographics of our relevant sample are generalizable to the university’s undergraduate
female population due to the relative similarities of the sample characteristics for gender
and ethnicity to that of the university population. Non-traditional female students and
female graduate students were underrepresented.

Figure 1
TABLE 1. Demographic and behavioral characteristics of female undergraduate
respondents
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The majority responded that they had previously had sex (90.4%), and t-test results found
the average age of women who responded “Yes” to previously having sex to be 20.5 and
“No” to be 19.9 (P<0.014). T-test results showed that the majority of respondents did get
regular Pap tests (78.8%), and the mean age of those women who did get regular Pap
tests (20.6) was statistically significant (P<0.001) from those who did not (19.5). Also, the
mean number of sexual partners among women who got regular Pap tests (4.6) was
statistically significant (P<0.001) from those women who did not get regular Pap tests
(2.4).
The majority of respondents both knew what HPV was (85%) and had heard of the HPV
vaccine, Gardasil ® (85%), prior to completing this survey. The mean age of those who
had heard of Gardasil ® (20.4) was statistically different (P<0.022) from those who were
not sure (18.7). The majority of respondents who knew what HPV was had also heard of
Gardasil ® (92%), but there was some inconsistency. For instance, of the participants
who did not know what HPV was, 28.6% had heard of Gardasil ® .
The most common sources of information about the HPV vaccine among respondents
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were the “Tell Someone” television commercial (64.9%) and the “One Less” television
commercial (64.5%), both of which were developed by Merck Pharmaceuticals, Inc.
Friends (41.8%) and family (31.9%) were the next most common sources of information
regarding the HPV vaccine.
The majority of respondents would get the vaccine if it were offered for free (75.3%), and
reasons for not getting the vaccine included “Need more information” (63.5%) and “Safety
concerns” (39.4%). “Speaking to physician” (45.5%) and “Sharing your knowledge with
others” (41.6%) were the most common behavior changes noted by respondents as a
result of knowing about the HPV vaccine. There was a population of participants (16.2%)
who answered that they had begun the HPV vaccination series. The mean age for those
“early adopters” was 19.7 years. There was a statistically significant correlation (P<0.001)
between those who had received the HPV vaccine and those who agreed that females
between the ages of nine and 26 should get the HPV vaccine and were likely to
recommend the vaccine to others.
We found several statistically significant associations between demographic variables and
attitudes and behaviors with respect to the HPV vaccine. More than half of the
respondents (52.9%) marked that “Yes,” they were concerned about possibly acquiring
HPV. With cross-tabulation analysis, we found statistically significant associations
between concern of acquiring HPV with each of the following variables: number of sexual
partners (P<0.029); knowledge of HPV (P<0.002); if ever had sex (P<0.001); and current
relationship status (P<0.001).
The majority of respondents (69.1%) were likely to recommend that others be vaccinated
against HPV. The mean age for those respondents who were likely to recommend the
HPV vaccine (20.4) was statistically different (P<0.025) from those who were not likely to
recommend the HPV vaccine (19.6). Statistically significant associations were also found
between the likelihood of recommending the HPV vaccine and the following variables:
knowledge of HPV (P<0.001); knowledge of the HPV vaccine (P<0.001); if ever had sex
(P<0.029); and if get regular Pap tests (P<0.002).
A high percentage of respondents (82.8%) agreed that females between the ages of nine
and 26 should be vaccinated. Statistically significant associations with this statement
were with knowledge of HPV (P<0.006) and current relationship status (P<0.022).
Finally, we addressed the controversial idea that vaccination against a sexually
transmitted infection, specifically HPV, may encourage risky sexual behavior. The
majority of respondents (65.3%) disagreed with this idea. The mean age of respondents
who disagreed (20.6) was statistically different (P<0.03) from those who agreed (19.9).
The most statistically significant correlations were found with this question and the
following variables: knowledge of HPV (P<0.001); knowledge of the HPV vaccine
(P<0.001); if ever had sex (P<0.001); number of sexual partners (P<0.021); age (P<0.04);
and if get regular Pap tests (P<0.001) (Table 2).

Figure 2
TABLE 2. Characteristics of female undergraduate respondents and their belief that HPV
vaccination may encourage risky sexual behavior
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Discussion
The public health benefits of HPV vaccination would be expected to significantly reduce
HPV-related morbidity, treatment, and overall U.S. economic burden, which is estimated
at more than $5 billion annually. 27 In addition, the HPV vaccine also has the potential to
prevent cervical cancer cases that are currently undetected due to a lack of Pap test
screening. 9 Although this population of female college students surveyed had heard of
HPV and the HPV vaccine, the lack of knowledge was the predominant reason
respondents would not get the HPV vaccine even if it were offered for free. In order to
dispel a false sense of security among this at-risk population, our findings warrant
integrated public health efforts among health educators on college campuses and in the
private sector, among parents and community health professionals, to name a few
resources, with respect to HPV infection and cervical cancer control via health behavior
education. These coordinated public health education strategies should involve primary
(e.g., HPV vaccination) and secondary (e.g., screening and early detection) prevention
methods to significantly reduce the burden of these preventable illnesses among this
vulnerable female population.
Previous studies have shown that college students have very little knowledge about HPV.
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In contrast, our results suggest that the majority (85%) of female college students in

our study do know what HPV is and have previously heard of the HPV vaccine, Gardasil
®

. Interestingly, knowledge of HPV did not correlate directly to knowledge of the HPV

vaccine. Conversely, 28.6% of women who did not know what HPV was, had heard of
Gardasil ® . The “Tell Someone” and “One Less” television commercials developed by
Merck Pharmaceuticals, Inc., were the most common sources of information about the
HPV vaccine. Continued use of the media will be important to incorporate into future
public health education and awareness efforts. While informing the viewer, the
commercials also stress the importance of sharing knowledge with others. Family and
friends were the next most common source of information about the HPV vaccine, and
sharing knowledge with others was a behavior change noted by the respondents.
Our study results indicate strong correlations of self-reported knowledge about HPV and
the HPV vaccine with the following themes:
Decision to get the HPV vaccine if it were offered for free. Although the majority (75.3%) of
women were likely to receive the HPV vaccine if it were offered for free, the remainder of
women responded “No” or “Not sure.” The most common reason for this was “Need more
information.” The respondents expressed that they do not feel they have enough
information to decide to get the HPV vaccine, even if it were offered for free. The women
also expressed concerns about safety of the HPV vaccine, which is understandable as
Gardasil ® is a new vaccine. Only 7% responded that they “Do not think the HPV vaccine
is important.”
Likelihood of recommending the HPV vaccine to others and the belief that HPV
vaccination will promote risky sexual behavior. Awareness of the HPV vaccine was
another behavior that correlated significantly with the likelihood of recommending the
vaccine to others and agreement that vaccination may encourage risky sexual behavior.
Of those women who have heard of the HPV vaccine, 73.3% were likely to agree that
others get the HPV vaccine. Of those women who had never heard of the HPV vaccine,
41.5% were likely to recommend it and 43.9% were not sure if they would recommend the
HPV vaccine. In general, awareness of the HPV vaccine correlated with women being
more likely to recommend the HPV vaccine and with disagreement that HPV vaccination
may encourage risky sexual behavior. Interestingly, all of the women who were not sure
what the HPV vaccine was were likely to recommend it and also agreed that HPV
vaccination may encourage risky sexual behavior. This information suggests that these
women may not view risky sexual behavior with a negative connotation since they are
likely to recommend a vaccine that they think encourages risky sexual behavior.
Furthermore, the age of the respondents significantly correlated with agreement that HPV
vaccination may encourage risky sexual behavior with older respondents disagreeing with
this belief. These findings highlight the need for health behavior education regarding risky
sexual activity and how to prevent HPV infection.
Agreement that females between the ages of nine and 26 should get the HPV vaccine.
Interestingly, 82.8% of respondents agreed that females between the ages of nine and 26
should be vaccinated, as compared to “likely” recommending that others receive the HPV
vaccine. This may very well be due to women not feeling informed enough to responsibly
recommend that others receive the vaccine. However, when asked whether to agree or
disagree, women felt more comfortable agreeing that females between the ages nine and
26 should be vaccinated.
Relationship status. Current relationship status of the respondents was a characteristic
that provided statistically significant correlations with concern about possibly acquiring
HPV and agreement that females between the ages nine and 26 should receive the HPV
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vaccine. Of those women who were single or dating, the majority (56.1% and 58.8%,
respectively) were concerned about acquiring HPV. Of those in monogamous
relationships, 52.7% were concerned about acquiring HPV. Of those respondents who
were married or living with a partner, more than half (54.5%) did not know or were not
concerned about acquiring HPV. While women who are married or in a monogamous
relationship may be at lesser risk for acquiring HPV, it is still a possibility. Therefore, this
data emphasizes the importance of increased health educational awareness efforts, as
women may be in high risk situations for acquiring HPV but not realize it. A majority of
women, regardless of relationship status, agreed that females between the ages of nine
and 26 should get the vaccine.
Sexual behavior and concern about possibly acquiring HPV. Of those women who
previously had sexual intercourse, only slightly more than half (56.5%) were concerned
about acquiring HPV. This low percentage leads us to believe that women may know
what HPV is, but they are not aware of the infectivity and prevalence of HPV, especially
among women of these vulnerable ages. Of those women who previously had sexual
intercourse, 70.2% were likely to recommend that others receive the HPV vaccine, and
68.3% disagreed that HPV vaccination may encourage risky sexual behavior. Of those
participants who had not had previous sexual intercourse, 60.7% were also likely to
recommend that others receive the HPV vaccine, and 32.1% agreed that HPV
vaccination may encourage risky sexual behavior. The data illustrates that sexual
experience does significantly influence attitudes and behaviors toward the HPV vaccine.
Number of sexual partners. The number of sexual partners was another characteristic that
provided statistically significant correlations. For example, with an increasing number of
sexual partners from zero to more than six, there was an increase in the percentage of
respondents who were concerned about acquiring HPV. A previous study found that HPV
seropositivity increased with the number of sexual partners, from 10% with one partner, to
25% with two or three partners, and up to 53% with more than six partners. 31 Another
study reported that each additional sexual partner added approximately 10% to the risk of
acquiring HPV infection. 32 However, in our study, of those women who have had more
than six sexual partners, 20% were not concerned about acquiring HPV. This is an
alarming statistic that warrants the implementation of further public health HPV
educational programs. It is possible that these women may feel comfortable with high-risk
sexual activity if they believe they are protected from HPV infection by vaccination, hence
a false sense of security. 30 In addition, there is a concern that an effective HPV vaccine
would cause sexually active women to significantly reduce their adherence to obtaining
Pap screening tests, thus leading to a potential increase in cervical cancer cases. 33
These findings, again, point to the need for vaccine availability to be accompanied by
proper ancillary awareness education.
Risky behaviors. Furthermore, the age at which one first had sexual intercourse, condom
use, description of health status, and race did not provide statistically significant
correlations. However, the frequency distributions highlight risky behaviors among this
vulnerable population. For example, 18.3% of the respondents “Hardly ever” or “Never”
used condoms with their male partners. Condom use has been associated with
decreased risk of acquiring HPV among newly sexually active women. 21 The practice of
not using condoms potentially puts these respondents at a higher risk for acquiring HPV
infection.
Limitations. Although the findings from this exploratory analysis provide valuable insight
into female college student attitudes, behaviors, and beliefs about HPV and the HPV
vaccine, several limitations to this study should be noted. The sampling bias associated
with a non-probability sampling technique is similar to other HPV studies in college
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students and limits the generalizability of the findings from this study to female college
students attending other universities. Yet, the sampling of female students in various
classes and events provide enhanced representation. The sample characteristics were
similar to the demographics of the university population and support the generalizability of
findings for the sampled university. However, the findings cannot be applied to all female
college students and may not be reflective of all young women. Future studies should use
random samples from several universities to maximize the generalizability of the findings.
Missing data occurred randomly across all surveys. In addition, the results were limited by
the cross-sectional study design and compliance to the authenticity of self-reported
information, such as HPV and HPV vaccine awareness. Despite these limitations, our
findings have been appropriately qualified, and we propose that they provide valuable
insight regarding selected correlates associated with sexual behavior and HPV
vaccination. In addition, our findings warrant an educational intervention by health
educators who may find this information useful when attempting to develop integrated
public health education efforts that are targeted towards this at-risk population.
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